Back to all blog posts
Aiforia Technologies Plc Press Release November 4, 2024 at 09:00 a.m. EET
Aiforia, a trusted provider of deep learning artificial intelligence (AI) solutions for pathology and Paige, a leader in next-generation AI technology have formed a non-exclusive partnership aimed at integrating Paige’s Diagnostic AI* applications in the AiforiaⓇ Platform to provide customers with outstanding functionality and performance. The partnership includes joint commercial efforts and enables both companies to provide their customers with top-tier AI-powered workflows aimed at enhancing laboratory efficiency, diagnostic confidence, scientific discoveries, and patient care results.
“Paige is delighted to partner with Aiforia, as this will further strengthen our combined leadership in the pathology industry, drive adoption in life sciences and diagnostics and make our powerful AI solutions available to more patients.” says Peter Hamilton, GM of Diagnostics at Paige.
“This collaboration marks a milestone in our dedication to providing powerful AI-solutions that address the changing needs of pathology laboratories. Paige has been with us at the forefront of AI in pathology diagnostics, and integrating our solutions into a joint offering presents a compelling opportunity for both us and our clients,” says Jukka Tapaninen, CEO of Aiforia.
The collaboration will begin in the coming months by creating seamlessly integrated solutions for both clinical and preclinical laboratory workflows, and will also include product development initiatives around foundation models.
* Not intended to replace licensed medical professional diagnosis. In the US: For Research Use Only. Not for use in diagnostic procedures.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com
About Paige
Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-approved AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products.
For more information, visit www.paige.ai.